

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4919993

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
THOMAS W. VON GELDERN	03/01/2018
BRADLEY BACKES	03/02/2018
BING CHEN	03/01/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	UNITY BIOTECHNOLOGY, INC.
<b>Street Address:</b>	3280 BAYSHORE BLVD.
<b>City:</b>	BRISBANE
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94005
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15955474
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(858)350-2399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	8583502300
<b>Email:</b>	asgarcia@wsgr.com, patentdocket@wsgr.com
<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH & ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304
<b>ATTORNEY DOCKET NUMBER:</b>	44237-768.302
<b>NAME OF SUBMITTER:</b>	ASHLEY GARCIA
<b>SIGNATURE:</b>	/Ashley Garcia/
<b>DATE SIGNED:</b>	04/17/2018
<b>Total Attachments: 4</b>	
source=Unity 44237-768.302 Assignment as filed#page1.tif	
source=Unity 44237-768.302 Assignment as filed#page2.tif	
source=Unity 44237-768.302 Assignment as filed#page3.tif	
source=Unity 44237-768.302 Assignment as filed#page4.tif	

## PATENT ASSIGNMENT

Docket Number 44237-768.601

WHEREAS, the undersigned:

1. Thomas W. VON GELDERN  
4209 West Solon Road  
Richmond, Illinois 60071 (US)
2. Bradley BACKES  
152 Liberty Street  
San Francisco, California 94110 (US)
3. Bing CHEN  
1339 Luoxiu Road  
Building 26, Room 502  
Minhang District  
200237 Shanghai, P.R. China

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

**SYNTHESIS METHOD FOR PRODUCING ENANTIOMERICALLY PURE CIS-IMIDAZOLINE COMPOUNDS FOR PHARMACEUTICAL USE**

☒ for which a PCT application serial number PCT/CN2017/088787 was filed on June 16, 2017 in the CN Receiving Office of the Patent Cooperation Treaty;

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).



WHEREAS, UNITY BIOTECHNOLOGY, INC., a corporation of the state of Delaware, having a place of business at 3280 Bayshore Blvd., Brisbane, CA 94005 (US), (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

PATENT

REEL: 045565 FRAME: 0881

PATENT ASSIGNMENT		Docket Number 44237-768.601
<p>6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.</p> <p>IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:</p>		
Date: <u>3/1/2018</u>	 Thomas W. VON GELDERN	
Date: _____	Bradley BACKES	
Date: _____	Bing CHEN	
RECEIVED AND AGREED TO BY ASSIGNEE, UNITY BIOTECHNOLOGY, INC.		
Date: <u>21 MAR 2018</u>	Signature:  Name: <u>Keith Leonard</u> Title: <u>Chief Executive Officer</u>	

PATENT ASSIGNMENT

Docket Number 44237-768.601

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: \_\_\_\_\_  
Thomas W. VON HELDERN

Date: 3/2/19 \_\_\_\_\_  
Bradley BACKES

Date: \_\_\_\_\_  
Bing CHEN

RECEIVED AND AGREED TO BY ASSIGNEE: UNITY BIOTECHNOLOGY, INC.

Date: 21 MAR 2018 Signature: \_\_\_\_\_  
Name: Keith Leonard  
Title: Chief Executive Officer

# PATENT ASSIGNMENT

Docket Number 44237-768.601

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.


IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: \_\_\_\_\_ Thomas W. VON GELDIERN

Date: \_\_\_\_\_ Bradley BACKES

Date: 3/1/2018 Bing Chen  
Bing CHEN

RECEIVED AND AGREED TO BY ASSIGNEE: UNITY BIOTECHNOLOGY, INC.

Date: 21 MAR 2018 Signature:   
Name: Keith Leonard  
Title: Chief Executive Officer